(Q33307767)

25 July 2017

0 references

1 reference

title

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective (English)

1 reference

25 July 2017

1 reference

Bart Heeg

1

1 reference

25 July 2017

Joep Damen

series ordinal

2

1 reference

25 July 2017

Ben Van Hout

series ordinal

3

1 reference

25 July 2017

1 January 2007

1 reference

25 July 2017

1 reference

25 July 2017

25

1 reference

25 July 2017

12

1 reference

25 July 2017

1063-1082

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200725120-00007

25 July 2017

0 references

cites work

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

12 December 2020

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

1 reference

12 December 2020

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease

1 reference

12 December 2020

The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial

1 reference

12 December 2020

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

1 reference

12 December 2020

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

12 December 2020

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness

1 reference

12 December 2020

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

1 reference

12 December 2020

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

1 reference

12 December 2020

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention

1 reference

12 December 2020

Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited

1 reference

12 December 2020

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

1 reference

12 December 2020

Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial

1 reference

12 December 2020

Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events

1 reference

12 December 2020

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling

1 reference

12 December 2020

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

1 reference

12 December 2020

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

12 December 2020

Short- and long-term prognosis after acute myocardial infarction in men versus women

1 reference

12 December 2020

1 reference

12 December 2020

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).

1 reference

12 December 2020

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

1 reference

12 December 2020

Cardiovascular disease risk profiles.

1 reference

12 December 2020

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

1 reference

12 December 2020

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

1 reference

12 December 2020

Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators

1 reference

12 December 2020

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

12 December 2020

Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty

1 reference

12 December 2020

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

12 December 2020

Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole

1 reference

12 December 2020

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

1 reference

12 December 2020

The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study

1 reference

12 December 2020

Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK)

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

12 December 2020

Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials

1 reference

12 December 2020

Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice

1 reference

12 December 2020

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden

1 reference

12 December 2020

CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction

1 reference

12 December 2020

1 reference

12 December 2020

Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis

1 reference

12 December 2020

Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study.

1 reference

12 December 2020

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK

1 reference

12 December 2020

Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack

1 reference

12 December 2020

Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention

1 reference

12 December 2020

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK

1 reference

12 December 2020

The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study

1 reference

12 December 2020

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

12 December 2020

10.2165/00019053-200725120-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference